We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.63%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$659M
AUM Growth
-$194M
Cap. Flow
-$205M
Cap. Flow %
-31.16%
Top 10 Hldgs %
43.01%
Holding
164
New
28
Increased
30
Reduced
27
Closed
56

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$15.1M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.4M
3
FOLD
Amicus Therapeutics
FOLD
+$11.3M
4
NMTR
9 Meters Biopharma
NMTR
+$9.54M
5
MRK icon
Merck
MRK
+$8.77M

Top Sells

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.9M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$9.22M
4
RXDX
Ignyta, Inc.
RXDX
+$9.19M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Healthcare 75.21%
2 Technology 4.55%
3 Financials 1.71%
4 Communication Services 1.32%
5 Consumer Discretionary 0.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SEE
101
DELISTED
Sealed Air
SEE
$193K 0.03%
4,500
– –
GLIBA
102
DELISTED
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
$159K 0.02%
+3,000
New +$157K
XRAY icon
103
Dentsply Sirona
XRAY
$2.68B
$126K 0.02%
2,500
– –
VSTO
104
DELISTED
Vista Outdoor Inc.
VSTO
$98K 0.01%
6,000
– –
LPSN icon
105
LivePerson
LPSN
$21.8M
$2K ﹤0.01%
+9
New +$1.8K
ATHX
106
DELISTED
Athersys, Inc. Common Stock
ATHX
$1K ﹤0.01%
31
– –
AAP icon
107
CALL
Advance Auto Parts
AAP
$3.35B
– –
-21,000
Closed -$2.09M
ACAD icon
108
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-170,000
Closed -$5.12M
ANAB icon
109
AnaptysBio
ANAB
$1.58B
– –
-35,000
Closed -$3.52M
ARDX icon
110
Ardelyx
ARDX
$1.22B
– –
-345,000
Closed -$2.28M
ATXS
111
DELISTED
Astria Therapeutics
ATXS
– –
-5,467
Closed -$489K
AXSM icon
112
Axsome Therapeutics
AXSM
$11.2B
– –
-301,000
Closed -$1.69M
BMRN icon
113
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-35,000
Closed -$3.12M
CDTX
114
DELISTED
Cidara Therapeutics
CDTX
– –
-40
Closed -$5K
CMG icon
115
Chipotle Mexican Grill
CMG
$47.2B
– –
-20,000
Closed -$116K
CPRX
116
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-576,825
Closed -$2.25M
CRBP icon
117
Corbus Pharmaceuticals
CRBP
$166M
– –
-12,500
Closed -$2.66M
CTSH icon
118
Cognizant
CTSH
$24.9B
– –
-55,086
Closed -$3.91M
CYTK icon
119
Cytokinetics
CYTK
$10.5B
– –
-210,000
Closed -$1.71M
ECL icon
120
Ecolab
ECL
$78.1B
– –
-2,000
Closed -$268K
GLMD icon
121
Galmed Pharmaceuticals
GLMD
$5.13M
– –
-1,323
Closed -$2.16M
HON icon
122
Honeywell
HON
$77B
– –
-29,612
Closed -$4.1M
IBB icon
123
PUT
iShares Biotechnology ETF
IBB
$9.34B
– –
-500,000
Closed -$53.4M
INCY icon
124
Incyte
INCY
$24.2B
– –
-50,000
Closed -$4.74M
INCY icon
125
PUT
Incyte
INCY
$24.2B
– –
-50,000
Closed -$4.74M
3 4
5
6 7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sphera Funds Management held 164 positions worth $659M, down 23% from $852M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Sphera Funds Management withdrew a net $205M in Q1 2018, closing 56 positions and reducing 27 holdings. Its most notable exit was Cellcom Israel, Ltd., an estimated $14M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 59% a quarter earlier, followed by Technology and Financials.

Against the trend, Sphera Funds Management opened a new position in Regeneron Pharmaceuticals worth $14.3M.

  • Sphera Funds Management's largest Q1 2018 buy was Regeneron Pharmaceuticals: 41,500 shares worth $14.3M.
  • Sphera Funds Management added most to Shire pic in Q1 2018, an estimated $15.1M increase.
  • Sphera Funds Management's biggest Q1 2018 reduction was Sarepta Therapeutics, cutting an estimated $9.07M.
  • Sphera Funds Management fully exited Cellcom Israel, Ltd. in Q1 2018, selling an estimated $14M.
  • Sphera Funds Management's ten largest holdings make up 43% of its $659M portfolio in Q1 2018.
  • Sphera Funds Management opened 28 new positions and closed 56 in Q1 2018.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $659M.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.